Back to search
FDAFDA · Food and drugs·Recall number D-1308-2022

Ativan Injection (lorazepam injection, USP), 2mg/mL, 1 mL vial, 25 vials per carton, RX Only, Manufactured by West-Ward Eatontown, NJ 07724, Carton NDC# 0641-6001-25, Vial NDC# 0641-6001-01

Published August 17, 2022 · Recall initiated: July 11, 2022

Summary

FDA records drug Class II recall D-1308-2022, published August 17, 2022 and initiated July 11, 2022. Recalling firm: Hikma Pharmaceuticals USA Inc.; Status: Terminated; Reported quantity: 301,400 vials; Lot: Lot # 060064Z, Exp. 06/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

What to do

Voluntary: Firm initiated · Letter

Get an email if ATIVAN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ATIVAN
Manufacturer
Hikma Pharmaceuticals USA Inc.
Distributor
Nationwide in the USA
Lot
Lot # 060064Z, Exp. 06/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ativan Injection (lorazepam injection, USP), 2mg/mL, 1 mL vial, 25 vials per carton, RX Only, Manufactured by West-Ward Eatontown, NJ 07724, Carton NDC# 0641-6001-25, Vial NDC# 0641-6001-01 recalled?

Yes. FDA published recall D-1308-2022 on August 17, 2022. Reported hazard: Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ATIVAN.